TCGA-EW-A1PC-01B-11R-A21T-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 6
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.590
- G2M_CHECKPOINT+0.520
- INTERFERON_ALPHA_RESPONSE+0.470
- DNA_REPAIR+0.360
- MYC_TARGETS_V2+0.310
- MYC_TARGETS_V1+0.300
- MITOTIC_SPINDLE+0.250
- SPERMATOGENESIS+0.250
- OXIDATIVE_PHOSPHORYLATION+0.230
- GLYCOLYSIS+0.210
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.450
- UV_RESPONSE_DN-0.440
- HEDGEHOG_SIGNALING-0.420
- TGF_BETA_SIGNALING-0.420
- ANDROGEN_RESPONSE-0.400
- KRAS_SIGNALING_UP-0.370
- TNFA_SIGNALING_VIA_NFKB-0.360
- ANGIOGENESIS-0.350
- IL6_JAK_STAT3_SIGNALING-0.350
- INFLAMMATORY_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG95 | — | — | 0.859 |
| 2 | SRR8518445 | — | C | 0.857 |
| 3 | SRR8518168 | — | E | 0.856 |
| 4 | TCGA-NC-A5HG-01A-11R-A26W-07 | — | cohortSQ1 | 0.854 |
| 5 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.853 |
| 6 | 96a00cc6-3880-4f03-a08d-73d284787971 | — | — | 0.840 |
| 7 | BS_DFGS950G | high-grade glioma | — | 0.839 |
| 8 | TCGA-66-2763-01A-01R-0851-07 | — | cohortSQ1 | 0.835 |
| 9 | TCGA-B6-A0RL-01A-11R-A084-07 | — | B | 0.835 |
| 10 | TCGA-58-A46M-01A-11R-A24H-07 | — | cohortSQ2 | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.060 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |